• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
World J Gastroenterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942.ABSTRACTHepatitis due to hepatitis B virus (HBV) reactivation can be serious and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving chemotherapy, especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation. Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver. The expression of these silent genomes is controlled by the immune system. Suppression or ablation of immune cells, most imp...
Source: World Journal of Gastroenterology : WJG - September 21, 2023 Category: Gastroenterology Authors: Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law Source Type: research

Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury
Wien Klin Wochenschr. 2023 Aug;135(Suppl 5):688-695. doi: 10.1007/s00508-023-02264-7. Epub 2023 Sep 20.ABSTRACTMembranoproliferative glomerulonephritis (MPGN) represents a heterogeneous group of diseases. The common feature of a membranoproliferative lesion pattern in the kidney biopsy can either be idiopathic/primary or-much more frequently-have a secondary cause. The historical classification into MPGN types I to III has largely been abandoned and replaced in recent years by a pathogenesis-oriented classification. A MPGN with C1q, C3 and/or C4 deposits on light microscopy is referred to as immune complex GN (IC-GN), whil...
Source: Wiener Klinische Wochenschrift - September 20, 2023 Category: General Medicine Authors: Michael Rudnicki Martin Windpessl Kathrin Eller Balazs Odler Philipp Gauckler Irmgard Neumann Emanuel Zitt Heinz Regele Andreas Kronbichler Karl Lhotta Marcus D S äemann Source Type: research

Association of giant cell hepatitis and autoimmune hemolytic anemia in infancy
Orv Hetil. 2023 Sep 10;164(36):1432-1436. doi: 10.1556/650.2023.32848. Print 2023 Sep 10.ABSTRACTGiant cell hepatitis associated with autoimmune hemolytic anemia (GCH-AIHA) is a rare disorder with unfavorable prognosis, affecting infants and young children. The mortality rate is high, complications of acute liver failure, sepsis, or liver transplantation can be responsible for fatal outcomes. An 18-month-old child who was diagnosed previously with autoimmune hemolytic anemia, developed acute hepatitis and acute liver failure concomitant to the relapse of the disease. GCH-AIHA is characterized by Coombs positive hemolytic a...
Source: Orvosi Hetilap - September 11, 2023 Category: General Medicine Authors: Katalin Csernus Alexandra T észás G ábor Ottóffy Antal Dezs őfi-Gottl Andr ás Tárnok Source Type: research

Hepatitis B virus-related cryoglobulinemia: Clinical characteristics, virological features, and treatment
CONCLUSIONS: HBV-related cryoglobulinemia patients should be treated with antiviral therapy. Corticosteroids and rituximab are effective for severe cases, but patients need to be closely monitored for therapy-related infection.PMID:37640269 | DOI:10.1016/j.virusres.2023.199212
Source: Virus Research - August 28, 2023 Category: Virology Authors: Hong-Xiao Han Wei Su Dao-Bin Zhou Jian Li Xin-Xin Cao Source Type: research

Hepatitis B Virus-Related Cryoglobulinemia: Clinical Characteristics, Virological Features, and Treatment
CONCLUSIONS: HBV-related cryoglobulinemia patients should be treated with antiviral therapy. Corticosteroids and rituximab are effective for severe cases, but patients need to be closely monitored for therapy-related infection.PMID:37640269 | DOI:10.1016/j.virusres.2023.199212
Source: Virus Research - August 28, 2023 Category: Virology Authors: Hong-Xiao Han Wei Su Dao-Bin Zhou Jian Li Xin-Xin Cao Source Type: research

Hepatitis B virus-related cryoglobulinemia: Clinical characteristics, virological features, and treatment
CONCLUSIONS: HBV-related cryoglobulinemia patients should be treated with antiviral therapy. Corticosteroids and rituximab are effective for severe cases, but patients need to be closely monitored for therapy-related infection.PMID:37640269 | DOI:10.1016/j.virusres.2023.199212
Source: Virus Research - August 28, 2023 Category: Virology Authors: Hong-Xiao Han Wei Su Dao-Bin Zhou Jian Li Xin-Xin Cao Source Type: research

Efficacy of Antiviral Prophylaxis up to 6 or 12 Months From Completion of Rituximab in Resolved Hepatitis B Patients: A Multicenter, Randomized Study
CONCLUSION: Prophylactic TDF up to 6 months after completion of rituximab-based chemotherapy is sufficient in terms of the efficacy and safety of reducing HBV reactivation in patients with resolved HBV.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02585947.PMID:37463687 | PMC:PMC10353911 | DOI:10.3346/jkms.2023.38.e216
Source: J Korean Med Sci - July 18, 2023 Category: General Medicine Authors: Heejoon Jang Su Jong Yu Hong Ghi Lee Tae Min Kim Yun Bin Lee Eun Ju Cho Jeong-Hoon Lee Jung-Hwan Yoon Yoon Jun Kim Source Type: research

Pages: 1  2  3  4  5  6  7  8